Table 1.
A summary of the articles discussed above regarding the effects of omega-3 PUFAs in cancer and cancer-treatment complications.
| Authors | Cancer-Related Complication | Species | Cancer Type | Treatment Scheme | Major Outcome |
|---|---|---|---|---|---|
| Hershmann et al., 2015 [96] | Aromatase-inhibitor associated arthralgia | Human | Breast cancer | 3.3 g 1 FO (560 mg EPA + DHA; 40:20) | Decreased pain, evaluated by the 2 BPI between the baseline and week 24 (p < 0.01) |
| Shen et al., 2018 [97] | Aromatase-inhibitor associated arthralgia | Human | Breast cancer (obese) | 3.3 g FO (560 mg EPA + DHA; 40:20) | Pain reduction in 3 BMI > 30 kg/m² patients (p = 0.02) |
| Martínez et al., 2018 [98] | Aromatase-inhibitor musculoskeletal symptoms (AIMSS) | Human | Breast cancer | 460 mg EPA + DHA 12.5 mg hydroxytyrosol 50 g curcumin |
Decrease of the BPI total score after 30 days (p = 0.011) |
| Ghroreishi et al., 2012 [99] | Paclitaxel-induced neuropathy | Human | Breast cancer | 640 mg FO (54% DHA + 10% EPA) | 70% did not develop neuropathy no pain score assessed |
| Maschio et al., 2018 [100] | Bortezomib-related neuropathy | Human | Multiple myeloma | Neuronorm® (400 mg DHA + 600 mg ALA) | Pain failed to increase significantly (p = 0.33) |
| Freitas et al., 2016 [11] | Cyclophosphamide-induced hemorrhagic cystitis | Mice | - | 20% FO-enriched diet or 1 µmol/kg i.p. | Decrease in spontaneous pain behavior and abdominal allodynia (p < 0.01) |
| Ye et al., 2018 [95] | Oral and paw cancer pain | Mice | Oral squamous cell carcinoma | RvD1 (100 ng or 200 ng) or RvD2 (100 ng or 200 ng) i.p. | RvD2 inhibited thermal and mechanical pain; RvD1 inhibited thermal pain |
1 FO: Fish oil; 2 BPI: Brief pain inventory; 3 BMI: body mass index.